A Study of Single Ascending Doses of LEM-S401 in Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective of the study is to assess the safety and tolerability of single dose of LEM-S401 in healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Lemonex; Lemonex Inc.
• Collaborator: Covance

Criteria

Inclusion Criteria:

• Healthy male and female subjects aged 19 to ≤65 years.

Exclusion Criteria:

• Significant history or clinical manifestation of any metabolic, allergic, dermatological (eg, contact dermatitis, atopic dermatitis), hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator (or designee).

• Positive urine drug screen at screening or check-in.

• If female, pregnant or breastfeeding.